Richard Lieberman1,2, Kevin P Jensen3,4, Kaitlin Clinton1, Eric S Levine2, Henry R Kranzler5,6, Jonathan Covault1. 1. From the, Alcohol Research Center, (RL, KC, JC), Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut, USA. 2. Department of Neuroscience, (RL, ESL), University of Connecticut School of Medicine, Farmington, Connecticut, USA. 3. Department of Psychiatry, (KPJ), Yale University School of Medicine, New Haven, Connecticut, USA. 4. VA Connecticut Healthcare System, (KPJ), West Haven, Connecticut, USA. 5. Center for Studies of Addiction, (HRK), Department of Psychiatry, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 6. VISN4 MIRECC, (HRK), Crescenz VAMC, Philadelphia, Pennsylvania, USA.
Abstract
BACKGROUND: There is growing evidence that the anticonvulsant topiramate is efficacious in reducing alcohol consumption. Further, an intronic single nucleotide polymorphism (rs2832407, C A) in the GRIK1 gene, which encodes the GluK1 subunit of the excitatory kainate receptor, predicted topiramate's effectiveness in reducing heavy drinking in a clinical trial. The molecular correlates of GRIK1 genotype that may relate to topiramate's ability to reduce drinking remain unknown. METHODS: We differentiated induced pluripotent stem cells (iPSCs) characterized by GRIK1 rs2832407 genotype from 8 A/A and 8 C/C donors into forebrain-lineage neural cultures. Our differentiation protocol yielded mixed neural cultures enriched for glutamatergic neurons. Basal mRNA expression of the GRIK1 locus was examined via quantitative polymerase chain reaction (qPCR). The effects of acute topiramate exposure on excitatory spontaneous synaptic activity were examined via whole-cell patch-clamp electrophysiology. Results were compared and contrasted between iPSC donor genotypes. RESULTS: Although characterization of the GRIK1 locus revealed no effect of rs2832407 genotype on GRIK1 isoform mRNA expression, a significant difference was observed on GRIK1 antisense-2 expression, which was greater in C/C neural cultures. Differential effects of acute exposure to 5 μM topiramate were observed on spontaneous synaptic activity in A/A versus C/C neurons, with a smaller reduction in excitatory event frequency observed in C/C donor neurons. CONCLUSIONS: This work highlights the use of iPSC technologies to study pharmacogenetic treatment effects in psychiatric disorders and furthers our understanding of the molecular effects of topiramate exposure in human neural cells.
BACKGROUND: There is growing evidence that the anticonvulsant topiramate is efficacious in reducing alcohol consumption. Further, an intronic single nucleotide polymorphism (rs2832407, C A) in the GRIK1 gene, which encodes the GluK1 subunit of the excitatory kainate receptor, predicted topiramate's effectiveness in reducing heavy drinking in a clinical trial. The molecular correlates of GRIK1 genotype that may relate to topiramate's ability to reduce drinking remain unknown. METHODS: We differentiated induced pluripotent stem cells (iPSCs) characterized by GRIK1rs2832407 genotype from 8 A/A and 8 C/C donors into forebrain-lineage neural cultures. Our differentiation protocol yielded mixed neural cultures enriched for glutamatergic neurons. Basal mRNA expression of the GRIK1 locus was examined via quantitative polymerase chain reaction (qPCR). The effects of acute topiramate exposure on excitatory spontaneous synaptic activity were examined via whole-cell patch-clamp electrophysiology. Results were compared and contrasted between iPSC donor genotypes. RESULTS: Although characterization of the GRIK1 locus revealed no effect of rs2832407 genotype on GRIK1 isoform mRNA expression, a significant difference was observed on GRIK1 antisense-2 expression, which was greater in C/C neural cultures. Differential effects of acute exposure to 5 μM topiramate were observed on spontaneous synaptic activity in A/A versus C/C neurons, with a smaller reduction in excitatory event frequency observed in C/C donor neurons. CONCLUSIONS: This work highlights the use of iPSC technologies to study pharmacogenetic treatment effects in psychiatric disorders and furthers our understanding of the molecular effects of topiramate exposure in human neural cells.
Authors: Henry R Kranzler; Reagan Wetherill; Richard Feinn; Timothy Pond; Joel Gelernter; Jonathan Covault Journal: Alcohol Clin Exp Res Date: 2014-12 Impact factor: 3.455
Authors: Bridget F Grant; S Patricia Chou; Tulshi D Saha; Roger P Pickering; Bradley T Kerridge; W June Ruan; Boji Huang; Jeesun Jung; Haitao Zhang; Amy Fan; Deborah S Hasin Journal: JAMA Psychiatry Date: 2017-09-01 Impact factor: 21.596
Authors: Henry R Kranzler; Jonathan Covault; Richard Feinn; Stephen Armeli; Howard Tennen; Albert J Arias; Joel Gelernter; Timothy Pond; Cheryl Oncken; Kyle M Kampman Journal: Am J Psychiatry Date: 2014-04 Impact factor: 18.112
Authors: Jonathan Covault; Timothy Pond; Richard Feinn; Albert J Arias; Cheryl Oncken; Henry R Kranzler Journal: Psychopharmacology (Berl) Date: 2014-02-21 Impact factor: 4.530
Authors: Apoorva Halikere; Dina Popova; Matthew S Scarnati; Aula Hamod; Mavis R Swerdel; Jennifer C Moore; Jay A Tischfield; Ronald P Hart; Zhiping P Pang Journal: Mol Psychiatry Date: 2019-09-03 Impact factor: 15.992
Authors: Eileen N Oni; Apoorva Halikere; Guohui Li; Alana J Toro-Ramos; Mavis R Swerdel; Jessica L Verpeut; Jennifer C Moore; Nicholas T Bello; Laura J Bierut; Alison Goate; Jay A Tischfield; Zhiping P Pang; Ronald P Hart Journal: Sci Rep Date: 2016-10-04 Impact factor: 4.379
Authors: Alexandra Goetjen; Maegan Watson; Richard Lieberman; Kaitlin Clinton; Henry R Kranzler; Jonathan Covault Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2020-10-07 Impact factor: 3.568